Canrenone on cardiovascular mortality in congestive heart failure: CanrenOne eFFects on cardiovascular mortality in patiEnts with congEstIve hearT failure: The COFFEE-IT study

Giuseppe Derosa, Pamela Maffioli, Laura Scelsi, Alessandro Bestetti, Massimo Vanasia, Arrigo F.G. Cicero, Luca Spinardi, Crescenzio Bentivenga, Daniela Degli Esposti, Massimiliano Caprio, Claudio Borghi, Bertram Pitt, Eugenio Cosentino

Research output: Contribution to journalArticle

Abstract

Aim: To evaluate canrenone effects compared to other therapies on cardiovascular mortality in patients with chronic heart failure (CHF) and preserved systolic function after 10 years of evaluation. Methods: We enrolled 532 patients with CHF and preserved systolic function. Patients were followed with a mean follow-up of 10 years: 166 patients were in therapy with canrenone, while 336 patients were in conventional therapy. We re-evaluated these data after 10 years, together with the rate of death and survival. Results: Systolic and diastolic blood pressure were lower with canrenone compared to the group not treated with canrenone, both in supine and orthostatism. In the group treated with canrenone we recorded a lower value of fasting plasma glucose and glycated hemoglobin. Uric acid was lower in the group treated with canrenone, no differences were observed regarding creatinine, sodium, potassium, brain natriuretic peptide (BNP), pro-BNP or plasma renin activity (PRA), while aldosterone levels were reduced in canrenone group compared to control. After 10 years, left ventricular mass was lower in canrenone group. We recorded a more pronounced progression of NYHA class in controls compared to patients treated with canrenone, with also a higher number of deaths. A higher number of deaths was recorded in control group in the 68–83 years range compared to canrenone. A higher incidence of death was reported among patients without hypercholesterolemia in control group; this was not significant in patients treated with canrenone. A longer survival was observed in patients treated with canrenone. Conclusion: Administered to patients with CHF and preserved systolic fraction, reduced mortality and extended the life.

Original languageEnglish
Pages (from-to)46-52
Number of pages7
JournalPharmacological Research
Volume141
DOIs
Publication statusPublished - Mar 1 2019

Fingerprint

Canrenone
Heart Failure
Mortality
Systolic Heart Failure
Brain Natriuretic Peptide
Blood Pressure
Control Groups
Glycosylated Hemoglobin A
Hypercholesterolemia
Uric Acid
Aldosterone

Keywords

  • Canrenone
  • Congestive heart failure
  • Long-Term mortality
  • Survival

ASJC Scopus subject areas

  • Pharmacology

Cite this

Canrenone on cardiovascular mortality in congestive heart failure : CanrenOne eFFects on cardiovascular mortality in patiEnts with congEstIve hearT failure: The COFFEE-IT study. / Derosa, Giuseppe; Maffioli, Pamela; Scelsi, Laura; Bestetti, Alessandro; Vanasia, Massimo; Cicero, Arrigo F.G.; Spinardi, Luca; Bentivenga, Crescenzio; Esposti, Daniela Degli; Caprio, Massimiliano; Borghi, Claudio; Pitt, Bertram; Cosentino, Eugenio.

In: Pharmacological Research, Vol. 141, 01.03.2019, p. 46-52.

Research output: Contribution to journalArticle

Derosa, Giuseppe ; Maffioli, Pamela ; Scelsi, Laura ; Bestetti, Alessandro ; Vanasia, Massimo ; Cicero, Arrigo F.G. ; Spinardi, Luca ; Bentivenga, Crescenzio ; Esposti, Daniela Degli ; Caprio, Massimiliano ; Borghi, Claudio ; Pitt, Bertram ; Cosentino, Eugenio. / Canrenone on cardiovascular mortality in congestive heart failure : CanrenOne eFFects on cardiovascular mortality in patiEnts with congEstIve hearT failure: The COFFEE-IT study. In: Pharmacological Research. 2019 ; Vol. 141. pp. 46-52.
@article{cced2e648a27459c9844cc3b5fc29fb8,
title = "Canrenone on cardiovascular mortality in congestive heart failure: CanrenOne eFFects on cardiovascular mortality in patiEnts with congEstIve hearT failure: The COFFEE-IT study",
abstract = "Aim: To evaluate canrenone effects compared to other therapies on cardiovascular mortality in patients with chronic heart failure (CHF) and preserved systolic function after 10 years of evaluation. Methods: We enrolled 532 patients with CHF and preserved systolic function. Patients were followed with a mean follow-up of 10 years: 166 patients were in therapy with canrenone, while 336 patients were in conventional therapy. We re-evaluated these data after 10 years, together with the rate of death and survival. Results: Systolic and diastolic blood pressure were lower with canrenone compared to the group not treated with canrenone, both in supine and orthostatism. In the group treated with canrenone we recorded a lower value of fasting plasma glucose and glycated hemoglobin. Uric acid was lower in the group treated with canrenone, no differences were observed regarding creatinine, sodium, potassium, brain natriuretic peptide (BNP), pro-BNP or plasma renin activity (PRA), while aldosterone levels were reduced in canrenone group compared to control. After 10 years, left ventricular mass was lower in canrenone group. We recorded a more pronounced progression of NYHA class in controls compared to patients treated with canrenone, with also a higher number of deaths. A higher number of deaths was recorded in control group in the 68–83 years range compared to canrenone. A higher incidence of death was reported among patients without hypercholesterolemia in control group; this was not significant in patients treated with canrenone. A longer survival was observed in patients treated with canrenone. Conclusion: Administered to patients with CHF and preserved systolic fraction, reduced mortality and extended the life.",
keywords = "Canrenone, Congestive heart failure, Long-Term mortality, Survival",
author = "Giuseppe Derosa and Pamela Maffioli and Laura Scelsi and Alessandro Bestetti and Massimo Vanasia and Cicero, {Arrigo F.G.} and Luca Spinardi and Crescenzio Bentivenga and Esposti, {Daniela Degli} and Massimiliano Caprio and Claudio Borghi and Bertram Pitt and Eugenio Cosentino",
year = "2019",
month = "3",
day = "1",
doi = "10.1016/j.phrs.2018.11.037",
language = "English",
volume = "141",
pages = "46--52",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press",

}

TY - JOUR

T1 - Canrenone on cardiovascular mortality in congestive heart failure

T2 - CanrenOne eFFects on cardiovascular mortality in patiEnts with congEstIve hearT failure: The COFFEE-IT study

AU - Derosa, Giuseppe

AU - Maffioli, Pamela

AU - Scelsi, Laura

AU - Bestetti, Alessandro

AU - Vanasia, Massimo

AU - Cicero, Arrigo F.G.

AU - Spinardi, Luca

AU - Bentivenga, Crescenzio

AU - Esposti, Daniela Degli

AU - Caprio, Massimiliano

AU - Borghi, Claudio

AU - Pitt, Bertram

AU - Cosentino, Eugenio

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Aim: To evaluate canrenone effects compared to other therapies on cardiovascular mortality in patients with chronic heart failure (CHF) and preserved systolic function after 10 years of evaluation. Methods: We enrolled 532 patients with CHF and preserved systolic function. Patients were followed with a mean follow-up of 10 years: 166 patients were in therapy with canrenone, while 336 patients were in conventional therapy. We re-evaluated these data after 10 years, together with the rate of death and survival. Results: Systolic and diastolic blood pressure were lower with canrenone compared to the group not treated with canrenone, both in supine and orthostatism. In the group treated with canrenone we recorded a lower value of fasting plasma glucose and glycated hemoglobin. Uric acid was lower in the group treated with canrenone, no differences were observed regarding creatinine, sodium, potassium, brain natriuretic peptide (BNP), pro-BNP or plasma renin activity (PRA), while aldosterone levels were reduced in canrenone group compared to control. After 10 years, left ventricular mass was lower in canrenone group. We recorded a more pronounced progression of NYHA class in controls compared to patients treated with canrenone, with also a higher number of deaths. A higher number of deaths was recorded in control group in the 68–83 years range compared to canrenone. A higher incidence of death was reported among patients without hypercholesterolemia in control group; this was not significant in patients treated with canrenone. A longer survival was observed in patients treated with canrenone. Conclusion: Administered to patients with CHF and preserved systolic fraction, reduced mortality and extended the life.

AB - Aim: To evaluate canrenone effects compared to other therapies on cardiovascular mortality in patients with chronic heart failure (CHF) and preserved systolic function after 10 years of evaluation. Methods: We enrolled 532 patients with CHF and preserved systolic function. Patients were followed with a mean follow-up of 10 years: 166 patients were in therapy with canrenone, while 336 patients were in conventional therapy. We re-evaluated these data after 10 years, together with the rate of death and survival. Results: Systolic and diastolic blood pressure were lower with canrenone compared to the group not treated with canrenone, both in supine and orthostatism. In the group treated with canrenone we recorded a lower value of fasting plasma glucose and glycated hemoglobin. Uric acid was lower in the group treated with canrenone, no differences were observed regarding creatinine, sodium, potassium, brain natriuretic peptide (BNP), pro-BNP or plasma renin activity (PRA), while aldosterone levels were reduced in canrenone group compared to control. After 10 years, left ventricular mass was lower in canrenone group. We recorded a more pronounced progression of NYHA class in controls compared to patients treated with canrenone, with also a higher number of deaths. A higher number of deaths was recorded in control group in the 68–83 years range compared to canrenone. A higher incidence of death was reported among patients without hypercholesterolemia in control group; this was not significant in patients treated with canrenone. A longer survival was observed in patients treated with canrenone. Conclusion: Administered to patients with CHF and preserved systolic fraction, reduced mortality and extended the life.

KW - Canrenone

KW - Congestive heart failure

KW - Long-Term mortality

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85058627381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058627381&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2018.11.037

DO - 10.1016/j.phrs.2018.11.037

M3 - Article

AN - SCOPUS:85058627381

VL - 141

SP - 46

EP - 52

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

ER -